BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 28108967)

  • 1. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
    Blohmer M; Zhu L; Atkinson JM; Beriwal S; Rodríguez-López JL; Rosenzweig M; Brufsky AM; Tseng G; Lucas PC; Lee AV; Oesterreich S; Jankowitz RC
    Breast Cancer Res; 2020 Jun; 22(1):70. PubMed ID: 32586354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
    Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
    BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.
    Lobbezoo D; Truin W; Voogd A; Roumen R; Vreugdenhil G; Dercksen MW; van den Berkmortel F; Smilde T; van de Wouw A; van Kampen R; van Riel J; Peters N; Peer P; Tjan-Heijnen VC
    Oncotarget; 2016 May; 7(20):29412-9. PubMed ID: 27121067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
    Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
    PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
    Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
    García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
    Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
    Arpino G; Bardou VJ; Clark GM; Elledge RM
    Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.
    Korhonen T; Kuukasjärvi T; Huhtala H; Alarmo EL; Holli K; Kallioniemi A; Pylkkänen L
    Breast; 2013 Dec; 22(6):1119-24. PubMed ID: 23863867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
    Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
    BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
    Pérez-Garcia J; Cortés J; Metzger Filho O
    Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
    Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
    World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.